---
title: "NervGen Pharma announces participation in investor conferences, CEO Adam Rogers to attend. TSXV: NGEN, NASDAQ: NGEN."
description: "NervGen Pharma Corp., a biopharmaceutical company based in Vancouver, British Columbia, revealed today that its President and CEO, Adam Rogers, MD, along with other executives, will be attending vario"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276229460.md"
published_at: "2026-02-18T12:32:37.000Z"
---

# NervGen Pharma announces participation in investor conferences, CEO Adam Rogers to attend. TSXV: NGEN, NASDAQ: NGEN.

> NervGen Pharma Corp., a biopharmaceutical company based in Vancouver, British Columbia, revealed today that its President and CEO, Adam Rogers, MD, along with other executives, will be attending various investor conferences in the near future. The company, listed on both TSXV (under the ticker NGEN) and NASDAQ (under the same ticker symbol), specializes in developing innovative treatments for spinal cord injuries and other neurotraumatic conditions. This announcement was made on February 18, 2026.

NervGen Pharma Corp., a biopharmaceutical company based in Vancouver, British Columbia, revealed today that its President and CEO, Adam Rogers, MD, along with other executives, will be attending various investor conferences in the near future. The company, listed on both TSXV (under the ticker NGEN) and NASDAQ (under the same ticker symbol), specializes in developing innovative treatments for spinal cord injuries and other neurotraumatic conditions. This announcement was made on February 18, 2026.

### Related Stocks

- [NGEN.US - NervGen Pharma](https://longbridge.com/en/quote/NGEN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NervGen Pharma 在慢性脊髓损伤的 1b/2a 期 CONNECT 研究中报告了积极的结果 | NervGen Pharma Corp. 宣布其针对慢性脊髓损伤的 1b/2a 阶段 CONNECT 研究取得积极结果。该公司将在 2026 年 2 月 15-17 日于华盛顿特区举行的 Unite2Fight Paralysis 第 20 | [Link](https://longbridge.com/en/news/275600172.md) |
| Valinor 和 Renew 启动合作伙伴关系，旨在生成用于神经疾病模型开发的最大临床多组学数据集 | Valinor Discovery 和 Renew Biotechnologies 宣布建立战略合作伙伴关系，旨在创建针对神经系统疾病的最大临床多组学数据集。此次合作旨在通过整合来自数千名患者的高分辨率数据和先进的机器学习技术，增强对疾病发 | [Link](https://longbridge.com/en/news/276745533.md) |
| AlzeCure Pharma 的疼痛项目 ACD440 获得了欧盟的孤儿药资格 | AlzeCure Pharma AB：PAIN PROJECT ACD440 在欧盟获得孤儿药资格 | [Link](https://longbridge.com/en/news/276726632.md) |
| 超过 3000 万美国人正在与罕见疾病抗争 | 美国罕见疾病国家组织（NORD）强调了超过 3000 万名罕见疾病患者所面临的挑战，其中不到 5% 的人拥有获批的治疗方案。NORD 呼吁在全球罕见疾病日（2 月 28 日）提高人们的意识，并将在 2 月 24 日举办国会简报，讨论患者倡导 | [Link](https://longbridge.com/en/news/276632841.md) |
| 11:17 ET 赢得你的荣誉：NORD 推出罕见病日®CME 挑战，旨在填补罕见病教育中的关键空白 | 为了纪念罕见病日，国家罕见疾病组织（NORD）推出了 “赢得你的条纹：罕见疾病继续医学教育挑战”，这是一个旨在增强医疗服务提供者对罕见疾病知识的全国性倡议。该活动从 2 月 23 日持续到 3 月 31 日，鼓励临床医生完成继续医学教育（C | [Link](https://longbridge.com/en/news/276624027.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.